Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-085 |
Synonyms | |
Therapy Description |
ABBV-085 (Samrotamab Vedotin) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) in conjugation with the cytotoxic agent, monomethyl auristatin E (MMAE), which may lead to cytotoxicity against LRRC15-expressing tumor cells (PMID: 29764866). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-085 | Samrotamab Vedotin|ABBV 085|ABBV085 | ABBV-085 (Samrotamab Vedotin) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) in conjugation with the cytotoxic agent, monomethyl auristatin E (MMAE), which may lead to cytotoxicity against LRRC15-expressing tumor cells (PMID: 29764866). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02565758 | Phase I | Gemcitabine Nivolumab Nab-paclitaxel ABBV-085 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors | Completed | USA | FRA | ESP | 0 |